PapersFlow Research Brief
Cholangiocarcinoma and Gallbladder Cancer Studies
Research Guide
What is Cholangiocarcinoma and Gallbladder Cancer Studies?
Cholangiocarcinoma and Gallbladder Cancer Studies is a field of medical research focused on the diagnosis, management, epidemiology, and therapeutic strategies for cholangiocarcinoma, including intrahepatic and hilar types, as well as gallbladder cancer.
This field encompasses 62,070 published works on topics such as surgical management, molecular pathology, and prognostic factors for biliary tract cancers. Studies address the increasing incidence and mortality rates of these cancers alongside emerging targeted therapies. Research also covers classification systems and treatment comparisons relevant to digestive system tumors.
Topic Hierarchy
Research Sub-Topics
Intrahepatic Cholangiocarcinoma Molecular Pathology
This sub-topic covers genomic profiling, mutations like IDH1/2 and FGFR fusions, and epigenetic changes in intrahepatic cholangiocarcinoma tumors. Researchers study these for classification and targeted therapy development using NGS data.
Surgical Resection for Hilar Cholangiocarcinoma
Focused on hepatectomy techniques, lymph node dissection, and R0 margins for hilar cholangiocarcinoma, this area evaluates perioperative outcomes and recurrence predictors. Studies include vascular reconstruction and liver transplantation feasibility.
Epidemiology of Biliary Tract Cancers
Researchers analyze rising incidence trends, risk factors like primary sclerosing cholangitis, liver flukes, and metabolic syndrome in cholangiocarcinoma and gallbladder cancer. It includes global disparities and population-based survival data.
Targeted Therapies in Cholangiocarcinoma
This sub-topic reviews FGFR inhibitors, IDH inhibitors, HER2-targeted agents, and immunotherapy trials in advanced cholangiocarcinoma. Clinical trials assess response rates, resistance mechanisms, and combination strategies.
Prognostic Factors in Gallbladder Cancer
Studies identify TNM staging refinements, biomarkers like CA19-9, and histopathological features predicting outcomes post-resection in gallbladder cancer. Research integrates nomograms and AI models for personalized prognostication.
Why It Matters
Studies in this field guide clinical decisions for biliary tract cancers, which have rising incidence and mortality. For instance, Valle et al. (2010) in "Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer" showed that cisplatin plus gemcitabine improved survival compared to gemcitabine alone in advanced biliary cancer patients, establishing it as a standard option without substantial added toxicity. Classifications like those in Nagtegaal et al. (2019) "The 2019 WHO classification of tumours of the digestive system" and Bosman (2010) "WHO Classification of Tumours of the Digestive System" inform pathology-based management across digestive tumors including biliary tract cancers. These findings support surgical and chemotherapeutic strategies in oncology practice.
Reading Guide
Where to Start
"Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer" by Valle et al. (2010), as it directly demonstrates a key survival benefit in advanced biliary cancer treatment with clear clinical trial results.
Key Papers Explained
Valle et al. (2010) "Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer" establishes chemotherapy standards for biliary tract cancer. Bosman (2010) "WHO Classification of Tumours of the Digestive System" provides foundational tumor classification relevant to cholangiocarcinoma and gallbladder cancer. Nagtegaal et al. (2019) "The 2019 WHO classification of tumours of the digestive system" builds on this with updates for digestive tumors, aiding precise diagnosis. Gottesman et al. (2002) "Multidrug resistance in cancer: role of ATP–dependent transporters" connects to therapy resistance challenges in these cancers.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current research emphasizes molecular pathology and prognostic factors amid rising biliary cancer incidence. Targeted therapies are emerging, as noted in field descriptions, though no recent preprints are available.
Papers at a Glance
Frequently Asked Questions
What is the standard chemotherapy for advanced biliary tract cancer?
Cisplatin plus gemcitabine provides a significant survival advantage over gemcitabine alone for advanced biliary tract cancer. Valle et al. (2010) in "Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer" reported this combination as an appropriate treatment option without substantial additional toxicity.
How does the WHO classify digestive system tumors including cholangiocarcinoma?
The WHO Classification of Tumours of the Digestive System outlines tumor types in the digestive tract, relevant to biliary cancers. Bosman (2010) detailed this in "WHO Classification of Tumours of the Digestive System", while Nagtegaal et al. (2019) updated it in "The 2019 WHO classification of tumours of the digestive system" for improved diagnostic precision.
What prognostic factors are studied in biliary tract cancer management?
Research examines epidemiology, surgical management, and molecular pathology as key prognostic factors. The field covers increasing incidence and mortality of biliary tract cancers, with therapeutic strategies like targeted therapies under investigation.
What role do multidrug resistance mechanisms play in cancer treatment including biliary cancers?
ATP-dependent transporters contribute to multidrug resistance in cancers. Gottesman et al. (2002) in "Multidrug resistance in cancer: role of ATP–dependent transporters" explained their impact on chemotherapy efficacy, applicable to biliary tract cancer therapies.
How has gemcitabine-based therapy been evaluated for biliary tract cancer?
Gemcitabine combined with cisplatin outperforms gemcitabine monotherapy in survival outcomes for advanced biliary cancer. This is evidenced by the trial in Valle et al. (2010) "Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer".
Open Research Questions
- ? What molecular subtypes distinguish intrahepatic from hilar cholangiocarcinoma for targeted therapy development?
- ? How can surgical resection criteria be refined to improve long-term survival in gallbladder cancer?
- ? Which prognostic factors best predict recurrence after treatment for biliary tract cancers?
- ? What combinations of chemotherapy beyond cisplatin-gemcitabine extend survival in advanced cases?
- ? How do histopathological classifications evolve to incorporate molecular pathology in cholangiocarcinoma?
Recent Trends
The field includes 62,070 works with sustained focus on epidemiology showing increasing incidence and mortality of biliary tract cancers.
Valle et al. "Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer" remains highly cited at 4268 citations for therapeutic strategies.
2010No recent preprints or news coverage in the last 12 months indicate steady rather than accelerating publication growth.
Research Cholangiocarcinoma and Gallbladder Cancer Studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Cholangiocarcinoma and Gallbladder Cancer Studies with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers